NCT03799094 is a Phase 1, PHASE2 clinical trial of Vitamin C in Carcinoma, Non-Small-Cell Lung, sponsored by Clifford Hospital, Guangzhou, China.

Who is sponsoring NCT03799094?

NCT03799094 is sponsored by Clifford Hospital, Guangzhou, China.

What drugs are being tested in NCT03799094?

Interventions in NCT03799094: Vitamin C, Tyrosine kinase inhibitor.

What condition does NCT03799094 study?

NCT03799094 studies Carcinoma, Non-Small-Cell Lung.

Is NCT03799094 still recruiting?

NCT03799094 is currently status unknown. Last updated 10 January 2019.

Last reviewed 2019-01-10 · How we verify

NCT03799094

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations

Status unknown Phase 1, PHASE2 Last updated 10 January 2019

What this trial tests

Phase 1, PHASE2 trial testing Vitamin C in Carcinoma, Non-Small-Cell Lung in 150 participants. Status unknown.

Timeline

5 December 2018

Primary endpoint
31 December 2020

31 December 2022

Quick facts

Lead sponsor	Clifford Hospital, Guangzhou, China
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	150
Start date	5 December 2018
Primary completion	31 December 2020
Estimated completion	31 December 2022
Sites	1 location across China

Drugs / interventions tested

Vitamin C — full drug profile →
Tyrosine kinase inhibitor — full drug profile →

Conditions studied

Carcinoma, Non-Small-Cell Lung — all drugs for Carcinoma, Non-Small-Cell Lung →

Sponsor

Clifford Hospital, Guangzhou, China

Who can join

Adults 18 to 75, any sex, with Carcinoma, Non-Small-Cell Lung. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial was to explore whether intravenous vitamin C can prolong resistance time of Tyrosine Kinase Inhibitor(TKI) on lung adenocarcinoma patients with Epidermal Growth Factor Receptor(EGFR) mutations, and can benefit NSCLC patients.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Iron and Cancer: 2020 Vision.
Torti SV, Torti FM. · · 2020 · cited 135× · PMID 32928919 · DOI 10.1158/0008-5472.can-20-2017
High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer.
Böttger F, Vallés-Martí A, Cahn L, Jimenez CR. · · 2021 · cited 119× · PMID 34717701 · DOI 10.1186/s13046-021-02134-y
The Role of Iron in Cancer Progression.
Guo Q, Li L, Hou S, Yuan Z, et al · · 2021 · cited 92× · PMID 34858857 · DOI 10.3389/fonc.2021.778492
Metabolic Regulation of Redox Balance in Cancer.
Purohit V, Simeone DM, Lyssiotis CA. · · 2019 · cited 79× · PMID 31288436 · DOI 10.3390/cancers11070955
Shining a light on metabolic vulnerabilities in non-small cell lung cancer.
Dowling CM, Zhang H, Chonghaile TN, Wong KK. · · 2021 · cited 23× · PMID 33130228 · DOI 10.1016/j.bbcan.2020.188462
Diverse antitumor effects of ascorbic acid on cancer cells and the tumor microenvironment.
Maekawa T, Miyake T, Tani M, Uemoto S. · · 2022 · cited 16× · PMID 36203466 · DOI 10.3389/fonc.2022.981547
Repurposing Vitamin C for Cancer Treatment: Focus on Targeting the Tumor Microenvironment.
Li WN, Zhang SJ, Feng JQ, Jin WL. · · 2022 · cited 13× · PMID 35681589 · DOI 10.3390/cancers14112608
A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity.
Lee CS, Sharma S, Miao E, Mensah C, et al · · 2020 · cited 8× · PMID 33117017 · DOI 10.2147/lctt.s258444

Verify or expand the search:

Other trials of Vitamin C

Trials testing the same drug.

NCT07476443 — Renoprotective Role of Vitamin C and Coenzyme Q10 in Nephrotoxicity · Phase 2, PHASE3 · not yet recruiting
NCT07414693 — Effect of Vitamin C on Length of Hospital Stay in Children With Severe Pneumonia · Phase 4 · recruiting
NCT06971315 — Impact of Vitamin C on Pain Detection and Tolerance Threshold · NA · completed
NCT06794255 — Exploratory Study on the Role of Vitamin C in Promoting Health in Middle-Aged and Elderly Adults · NA · recruiting
NCT07341308 — Does Vitamin C Increase the Body Heat Generated By The Nervous System? · NA · recruiting

Other recruiting trials for Carcinoma, Non-Small-Cell Lung

Currently open trials in the same condition.

NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting
NCT07222566 — Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adu · Phase 3 · recruiting
NCT07230691 — A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-Wor · recruiting
NCT07509333 — MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients · NA · recruiting
NCT07180862 — A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03799094 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Clifford Hospital, Guangzhou, China
Last refreshed: 10 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03799094.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing